Does St John's wort work for depression? What the trial evidence shows
Pooled trials put the herb roughly on a par with standard antidepressants for mild-to-moderate depression, with fewer dropouts for side effects. The catches are dangerous drug interactions and wildly variable products.
St John's wort genuinely has trial evidence behind it — more than most herbal remedies — and for mild-to-moderate depression the pooled data put it roughly level with standard antidepressants, with fewer people quitting because of side effects [s1][s2]. That is a real finding, not folklore. But two serious catches sit underneath it: the products sold to consumers vary enormously in strength, and the herb interacts dangerously with a long list of common medicines. The honest verdict is "effective in trials, but not to be treated as a harmless natural alternative."
What the pooled trials found
The most authoritative synthesis is a Cochrane review that combined 29 randomised, double-blind trials in 5,489 patients with major depression — 18 comparisons against placebo and 17 against standard antidepressants [s1]. Against placebo, the herb came out ahead: in the nine larger, more rigorous trials the response rate ratio was 1.28 (95% CI 1.10 to 1.49), and in nine smaller trials a larger but less reliable 1.87 (95% CI 1.22 to 2.87) [s1]. Against the drugs, the results were strikingly even. Compared with older tricyclic antidepressants the response rate ratio was 1.02 (95% CI 0.90 to 1.15), and compared with SSRIs it was 1.00 (95% CI 0.90 to 1.11) — essentially a dead heat [s1].
A 2017 meta-analysis in the Journal of Affective Disorders reached the same place with newer numbers, pooling 27 trials of 3,808 patients against SSRIs [s2]. It found comparable response (relative risk 0.983, 95% CI 0.924 to 1.042) and remission (relative risk 1.013, 95% CI 0.892 to 1.134), and a significantly lower dropout rate on St John's wort (odds ratio 0.587, 95% CI 0.478 to 0.697) [s2]. On symptom scores the difference from SSRIs was negligible (standardised mean difference −0.068, 95% CI −0.127 to 0.021) [s2].
Tolerability looks like a genuine advantage
The consistent bright spot is side effects. In the Cochrane review, patients on St John's wort dropped out because of adverse effects far less often than those on older antidepressants (odds ratio 0.24, 95% CI 0.13 to 0.46) and less often than those on SSRIs (odds ratio 0.53, 95% CI 0.34 to 0.83) [s1]. The 2017 analysis echoed that lower discontinuation [s2]. For people who abandon antidepressants because of nausea, sexual side effects or grogginess, that is not a trivial difference.
The catches the trials expose
The efficacy figures come wrapped in warnings. Both reviews found that where a study was done shaped its result: trials from German-speaking countries, where the herb is licensed and widely prescribed, reported findings more favourable to St John's wort, and the Cochrane authors cautioned that this link between a study's origin, its precision and its effect size complicates the whole interpretation [s1]. The 2017 review added that the evidence is short-term — every trial ran just 4 to 12 weeks — and that it remains unclear whether the herb helps people with severe depression or high suicidality, precisely the patients for whom getting treatment right matters most [s2].
There is also a problem the trials cannot fix: consistency. The "St John's wort" tested in a standardised trial extract is not necessarily what sits in a supermarket bottle, where the dose and composition of active compounds can differ widely between brands and batches, so a positive trial does not guarantee a given product delivers the same thing.
The safety issue that changes the calculus
The most important caveat is not about whether it works but about what it does to other drugs. St John's wort is a potent inducer of the body's drug-metabolising enzymes, and it can weaken or dangerously interact with a long list of prescription medicines — including other antidepressants, the contraceptive pill, blood thinners, some heart and HIV drugs, and immunosuppressants. Combined with an SSRI it can also raise the risk of excess serotonin. This is why "natural" is the wrong mental category: an active compound strong enough to match an antidepressant is strong enough to cause harm, and it should not be started, stacked or stopped without a clinician who knows the rest of the medicine list.
What it means
For mild-to-moderate depression, St John's wort is one of the few over-the-counter options with real trial support, and its tolerability is a genuine edge [s1][s2]. But the evidence is short-term and uneven, the products are inconsistent, and the interaction risk is serious enough that it is a prescription-grade decision in all but name [s2]. For how exercise compares as a non-drug option, see does exercise beat antidepressants. This article describes evidence and is not medical advice.
Sources
- St John's wort for major depression — Cochrane Database of Systematic Reviews, 2008-10-08
- Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis — Journal of Affective Disorders, 2017-01-03
Sources
- St John's wort for major depression — Cochrane Database of Systematic Reviews , October 8, 2008
- Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis — Journal of Affective Disorders , January 3, 2017
More on
What helps prolonged grief? A targeted therapy beats an antidepressant
In two randomised trials, a grief-specific psychotherapy roughly doubled response rates against strong comparators. Citalopram alone did not beat placebo — but it did help the depression that often travels with grief.
Adding aripiprazole beat switching drugs in resistant depression in older adults
In a 619-patient NEJM trial of treatment-resistant depression after 60, augmenting an antidepressant with aripiprazole improved well-being more than switching to bupropion. The margin was modest.
Does exercise beat antidepressants for depression? The head-to-head evidence
In the trial that pitted them against each other, aerobic exercise matched sertraline on remission. But both sat only a little above a strikingly strong placebo, which is the part the headlines skip.
Antidepressants differ by 4 kg and 21 beats per minute, network analysis finds
Pooling 151 studies and 58,534 participants across 30 drugs, researchers ranked antidepressants by physiological side effects rather than efficacy. Some drugs raised cholesterol while reducing body weight.